Company
A Research Laboratory, Not a Marketing Department
General Biotech is a research and development organization engineering biotechnology compounds that influence multiple neurological signaling systems with precision.
- Focus
- Neuromodulation R&D
- Lead program
- GB-101 Synaptiva
- Stage
- Preclinical research
- Disciplines
- Chemistry · Computation · Neuroscience
Principles
How we work
Mechanism before narrative
Every claim we make traces to a defined molecular mechanism, a model, or an experiment — and we label which one it is.
Prediction is a hypothesis
Computationally predicted activity is stated as prediction until assays confirm it. We do not promote unvalidated pharmacology.
Selectivity is a feature
Designing for multiple activities requires equal rigor in designing against the ones we do not want.
Build the platform, not the pitch
Each program is expected to leave behind reusable models, methods and data for the programs that follow.
Team
The people building General Biotech
Guilherme Murad
Mastermind behind the development of molecules and the chemical principles that define them.
Filippo Fiorentino
Turns molecule and product development into a venture — building the business around the science.
Contact
Research and partnership inquiries
We work with research groups, computational chemistry partners and investors interested in multimodal neurological compounds.
Preclinical research program. GB-101 Synaptiva is investigational and has not been evaluated or approved by any regulatory authority.